Prolonged Exposure + MIDOMAFETAMINE for stress disorders, post-traumatic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Nov 2023: Trial registered, NCT06117306
  2. 25 Oct 2024: Trial started, NCT06117306

The trials

NCT06117306: MDMA-assisted Massed Prolonged Exposure for PTSD

State
Under way
Phase
Phase 3
People
20 planned
Started
25 Oct 2024
Primary completion
Mar 2027
Arms
Dose A (exact dose not disclosed), Dose B (exact dose not disclosed)
Results
None posted
  1. 7 Nov 2023: Trial registered
  2. 25 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.